Publication | Open Access

DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

New Oral Nlrp3Early Phase 2AAntiviral TherapyRespiratory InfectionInfectious Respiratory DiseaseCovid-19Covid-19 Pneumonia